PF4V1
Platelet factor 4 variant
Also known as: CXCL4L1, CXCL4V1, PF4V_HUMAN, SCYB4V1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P10720
- Gene
- PF4V1
- Ensembl
- ENSG00000109272
- Chromosome
- 4
- Canonical length
- 104 aa
- Protein class
- Plasma proteins, Predicted secreted proteins
- Secretome location
- Secreted to blood
- Quaternary structure
- Homotetramer
OverviewNCBI Gene
The protein encoded by this gene is a chemokine that is highly similar to platelet factor 4. The encoded protein displays a strong antiangiogenic function and is regulated by chemokine (C-X-C motif) receptor 3. This protein also impairs tumor growth and can protect against blood-retinal barrier breakdown in diabetes patients. [provided by RefSeq, Nov 2015]
Canonical amino-acid sequenceUniProt
104 residues, UniProt reviewed canonical sequence.
>P10720|PF4V1
1 MSSAARSRLT RATRQEMLFL ALLLLPVVVA FARAEAEEDG DLQCLCVKTT SQVRPRHITS
61 LEVIKAGPHC PTAQLIATLK NGRKICLDLQ ALLYKKIIKE HLESLocalizationUniProt · AlphaFold · HPA
Whether an antibody against PF4V1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.47
- Highest tissue expression
- 2.7 nTPM
Expression across tissuesHPA
Tissue
- spleen: 2.7 nTPM
- duodenum: 1.6 nTPM
- bone marrow: 1.1 nTPM
- seminal vesicle: 1 nTPM
- small intestine: 0.9 nTPM
- kidney: 0.7 nTPM
Single-cell type
- platelets: 2,137 nCPM
- megakaryocytes: 544 nCPM
- cholangiocytes: 19 nCPM
- respiratory secretory cells: 17 nCPM
- neuroendocrine cells: 17 nCPM
- conjunctival goblet cells: 15 nCPM
Immune cell
- basophil: 13 nTPM
- total PBMC: 9.9 nTPM
- neutrophil: 9.2 nTPM
- plasmacytoid DC: 0.2 nTPM
- classical monocyte: 0.1 nTPM
- naive B-cell: 0.1 nTPM
Brain region
- cerebral cortex: 0.7 nTPM
- basal ganglia: 0.4 nTPM
- hypothalamus: 0.3 nTPM
- pons: 0.3 nTPM
- thalamus: 0.3 nTPM
- choroid plexus: 0.2 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.91
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.05
- DepMap mean gene effect
- 0
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- antimicrobial humoral immune response mediated by antimicrobial peptide
- cellular response to lipopolysaccharide
- inflammatory response
- neutrophil chemotaxis
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PF4V1 as an antibody target. Whether an autoantibody or antibody against PF4V1 could matter depends on whether native PF4V1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PF4V1 is annotated as secreted, so native PF4V1 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label PF4V1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...